<DOC>
	<DOCNO>NCT00494546</DOCNO>
	<brief_summary>Objective : The objective study test hypothesis deliver high percentage radiation dose external radiation versus implant lead high tumor control rate . Research design A total 600 patient AJC clinical stage T1-T2 prostatic carcinoma ( Gleason grade 7 10 and/or PSA 10 20 ng/ml ) randomize treatment 44 Gy versus 20 Gy external radiation plus Pd-103 implant boost ( 90 Gy versus 105 Gy , respectively ) .</brief_summary>
	<brief_title>High Versus Low Dose Supplemental External Radiation With Pd-103 Prostate Cancer</brief_title>
	<detailed_description>Objective : The objective study test hypothesis deliver high percentage radiation dose external radiation versus implant lead high tumor control rate . Research design A total 600 patient AJC clinical stage T1-T2 prostatic carcinoma ( Gleason grade 7 10 and/or PSA 10 20 ng/ml ) randomize treatment 44 Gy versus 20 Gy external radiation plus Pd-103 implant boost ( 90 Gy versus 105 Gy , respectively ) . Methodology : Patients randomize method random permute block . Cancer status monitor serial serum PSA 6 , 12 , 18 24 month yearly thereafter . Treatment-related morbidity monitor personal interview , use standard American Urologic Association Radiation Therapy Oncology Group criteria 1 , 3 , 6 , 12 24 month . The primary endpoint base serum PSA . A value 1.0 ng/ml two year treatment consider residual recurrent cancer fail therapy . Findings : 566 patient randomize study close due slow accrual . A preliminary analysis show similar morbidity treatment arm , nearly identical cancer control rate randomization arm .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Males Prostate cancer PSA 1020 Gleason score 710 Lymph node positive</criteria>
	<gender>Male</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>prostate</keyword>
	<keyword>brachytherapy</keyword>
</DOC>